Document:

Exhibit 10.1

 

BioSolar, Inc. has requested that portions of this
document be accorded confidential treatment pursuant 

to Rule 24b-2 promulgated under the Securities Exchange Act of 1934, as amended.

 

 

RESEARCH
AGREEMENT

 

THIS
AGREEMENT effective this 16 day of Aug, 2016, by and between BioSolar Inc., (hereinafter referred to as "Sponsor") and
North Carolina Agricultural and Technical State University, a constituent member of the University of North Carolina system (hereinafter
referred to as "University"); individually referred to as "Party" or collectively as "Parties".

 

Witnesseth:

 

WHEREAS,
the research program contemplated by this Agreement is of mutual interest and benefit to University and to Sponsor, will further
the instructional and research objectives of University in a manner consistent with its status as a non-profit, tax-exempt, educational
institution, and may derive benefits for both Sponsor and University through inventions, improvements, and/or discoveries;

 

NOW,
THEREFORE, in consideration of the premises and mutual covenants herein contained, the Parties hereto agree to the following:

 

Article
1 - Definitions

 

As
used herein, the following terms shall have the following meanings:

 

	1.1	"Project"
                                         shall mean the research, testing and evaluation of the research program as described
                                         in the proposal entitled, "[***]" submitted on or about Aug 3, 2016,
                                         hereof, with Sung-Jin Cho to serve as the University Principal Investigator.
	 	 
	1.2	"Contract
                                         Period" is from September 12, 2016 through September 11, 2017
	 	 
	1.3	"Intellectual
                                         Property" shall mean, but is not limited to, any invention, copyright, provisional
                                         patent, patent, trademark, trade secret, software or the like which is either owned by
                                         one of the Parties or is developed in the course of executing this Project.

 

Article
2 - Research Work

 

	2.1	University
                                         shall commence the performance of Project promptly after the effective date of this Agreement,
                                         and shall use reasonable efforts to perform such Project substantially in accordance
                                         with the terms and conditions of this Agreement. Anything in this Agreement to the contrary
                                         notwithstanding, Sponsor and University may at any time amend Project by mutual written
                                         agreement.
	 	 
	2.2	In
                                         the event that the Principal Investigator becomes unable to continue Project, and a mutually
                                         acceptable substitute is not available, University and/or Sponsor shall have the option
                                         to terminate said project.

 

 

Confidential materials omitted and filed separately
with the Securities and Exchange

Commission. Asterisks denote such omission.

     

     

    

BioSolar,
Inc. has requested that portions of this document be accorded confidential treatment pursuant

to Rule 24b-2 promulgated under
the Securities Exchange Act of 1934, as amended.

 

 

Article
3 - Reports and Conferences

 

	3.1	A
                                         written final report summarizing the findings shall be submitted by University within
                                         Sixty (60) days of the conclusion of the Contract Period, or early termination of this
                                         Agreement.
	 	 
	3.2	During
                                         the contract period of this Agreement, representatives of University will meet with representatives
                                         of Sponsor at times and places mutually agreed upon to discuss the progress and results,
                                         as well as ongoing plans, or changes therein, of Project to be performed hereunder.

 

Article
4 - Costs, Billings, and Other Support

 

	4.1	It
                                         is agreed to and understood by the Parties hereto that, subject to Article 2, total costs
                                         to Sponsor hereunder shall not exceed the sum of $123,993.00. Monthly payments
                                         will be made by Sponsor upon receipt of University invoices for costs incurred.
	 	 
	4.2	University
                                         shall retain title to any equipment purchased with funds provided by Sponsor under this
                                         Agreement.
	 	 
	4.3	Anything
                                         herein to the contrary notwithstanding, in the event of early termination of this Agreement
                                         by Sponsor pursuant to Article 9 hereof, Sponsor shall pay all costs accrued by University
                                         under this Agreement as of the date of termination, including non-cancelable obligations,
                                         which shall include all non-cancelable contracts and fellowships or postdoctoral associate
                                         appointments incurred prior to the effective date of termination but only to the extent
                                         that non-cancelable obligation directly relate to services under this Agreement. After
                                         termination, any obligation of Sponsor for fellowships or postdoctoral associates shall
                                         end no later than the end of University's academic year following termination.

 

Article
5 - Publicity

 

		5.1	Sponsor
                                         will not use the name of University, nor of any member of University's Project staff,
                                         in any publicity, advertising, or news release without the prior written approval of
                                         the Vice Chancellor for Research and Economic Development of the University. University
                                         will not use the name of Sponsor, nor any employee of Sponsor, in any publicity without
                                         the prior written approval of Sponsor. However, nothing in this Article is intended to
                                         restrict either party from disclosing the existence of and nature of this Agreement (including
                                         the name of the other party) or from including the existence of and nature of this Agreement,
                                         in the routine reporting of its activities.

 

 

Confidential materials omitted and filed separately
with the Securities and Exchange

Commission. Asterisks denote such omission.

    	 	2	 

     

    

BioSolar,
Inc. has requested that portions of this document be accorded confidential treatment pursuant 

to Rule 24b-2 promulgated under
the Securities Exchange Act of 1934, as amended.

 

 

Article
6 - Publications

 

	6.1	Sponsor recognizes that under University policy, the
results of University Project may be publishable and agrees that Researchers engaged in Project may be permitted to present at
symposia, national, or regional professional meetings, and to publish in journals, theses or dissertations, or otherwise of their
own choosing, methods and results of Project, provided, however, that Sponsor shall have been furnished copies of any proposed
publication or presentation at least thirty (30) days in advance of the submission of such proposed publication or presentation
to a journal, editor, or other third party. Sponsor shall have fifteen (15) days, after receipt of said copies, to object to such
proposed presentation or proposed publication because there is patentable subject matter which needs protection or the proposed
presentation or publication reveals Sponsor's proprietary information. In the event that Sponsor makes such objection, said Researcher(s)
shall refrain from making such publication or presentation for a maximum of six (6) months from date of receipt of such objection
in order for University to file patent application(s) with the United States Patent and Trademark Office and/or foreign patent
office(s) directed to the patentable subject matter contained in the proposed publication or presentation or remove Sponsor's
confidential information from the publication or presentation.

 

Article
7 - Intellectual Property

 

	7.1	All
                                         rights to inventions, improvements and/or discoveries, whether patentable or copyrightable
                                         or not, relating to Project made solely by employees of Sponsor shall belong to Sponsor.
                                         Such inventions, improvements, and/or discoveries shall not be subject to the terms and
                                         conditions of this Agreement.
	 	 
	7.2	All
                                         inventions, improvements and/or discoveries which are conceived and/or made solely by
                                         one or more employees of the University shall belong to University and shall be subject
                                         to the terms and conditions of this agreement.
	 	 
	7.3	Rights
                                         to inventions, improvements and/or discoveries, whether patentable or copyrightable,
                                         relating to project made jointly by employees of University and Sponsor shall belong
                                         jointly to the Parties. The University's undivided rights shall be governed in accordance
                                         with Article 8.1 below.
	 	 
	7.4	The University will promptly notify Sponsor
of any University Intellectual Property conceived and/or made during the Contract Period under Project.
	 	 
	7.5	All Confidential Information disclosed or received
by the Parties as a part of the Project shall be subject to the Non-disclosure Agreement effective on August 16, 2016.

 

Confidential materials omitted and filed separately
with the Securities and Exchange

Commission. Asterisks denote such omission.

    	 	3	 

     

    

BioSolar,
Inc. has requested that portions of this document be accorded confidential treatment pursuant 

to Rule 24b-2 promulgated under
the Securities Exchange Act of 1934, as amended.

 

 

Article
8 - Grant of Rights

 

	8.1	For
    Intellectual Property derived solely from the University's efforts, University hereby grants Sponsor a six-month option, commencing
    with the notice of invention, at Sponsor's sole selection, for:

 

	 	8.1.1	a
    non-exclusive, royalty-free, non-transferable, non-commercial research license for internal use; or
	 	 	 
	 	8.1.2	for
    consideration, a non-exclusive license without right to sublicense; or
	 	 	 
	 	8.1.3	a
    royalty-bearing, limited-term exclusive license (subject to third party rights, if any) including the right to sublicense,
    in the United States and/or any foreign country elected by the Sponsor (subject to 8.2 below) to make, have made, use, lease,
    sell, and import (in a designated field of use, where appropriate) products embodying or produced through the use of such
    invention, provided that the Sponsor agrees to reimburse N.C. A&T for the costs of patent prosecution and maintenance
    in the United States and any elected foreign country. This alternative is subject to N.C. A&T concurrence and the negotiation
    of commercially reasonable terms and conditions within three (3) months after selection of this alternative.
	 	 	 
	 	 	Such
    terms and conditions shall reflect the past and future contributions of the Parties to the project. In the event that the
    Sponsor has not elected any of the foregoing alternatives within six (6) months after notification that a patent application
    has been filed, the Sponsor shall be deemed to have elected a royalty-free internal research use license and to have forgone
    other alternatives.

 

Article
9 - Term and Termination

	9.1	This
                                         Agreement shall become effective upon the date first hereinabove written and shall continue
                                         in effect for the full duration of the contract period unless sooner terminated in accordance
                                         with the provisions of Article 2.2 and/or this Article. The Parties hereto may, however,
                                         extend the term of this Agreement for additional periods as desired under mutually agreeable
                                         terms and conditions which the Parties reduce to writing and sign. Either party may terminate
                                         this agreement, without liability to the other, except for the responsibilities outlined
                                         in Article 4.3 above, upon thirty (30) days prior written notice to the other.
	 	 
	9.2	In
the event that either party hereto shall commit any breach of default in any of the terms and conditions of this Agreement, and
also shall fail to remedy such default or breach within thirty (30) days after receipt of written notice thereof from the other
party hereto, the party giving notice may, at its option and in addition to any other remedies which it may have at law or in
equity, terminate this Agreement by sending notice of termination in
writing to the other party to such effect, and such termination shall be effective as of the date of the receipt of such notice.

 

 

Confidential materials omitted and filed separately
with the Securities and Exchange

Commission. Asterisks denote such omission.

    	 	4	 

     

    

BioSolar, Inc. has requested that portions of this document be accorded confidential treatment pursuant

to Rule 24b-2 promulgated under the Securities Exchange Act of 1934, as amended.

 

 

	9.3	Subject
                                         to Article 8, termination of this Agreement by either party for any reason shall not
                                         affect the rights and obligations of the Parties accrued prior to the effective date
                                         of termination of this Agreement. No termination of this Agreement, however effectuated,
                                         shall affect the Sponsor's rights and duties under Article 7 hereof, or release the Parties
                                         hereto from their rights and obligations under Articles 4, 5, 6, 7, 8, and 10.

 

Article
10 - Independent Contractor

 

	10.1	In the performance of all service hereunder:

 

	 	10.1.1	University shall be deemed to be and shall be an independent
contractor and, as such, University shall not be entitled to any benefits applicable to employees of Sponsor.
	 	 	 
	 	10.1.2	Neither party is authorized or empowered to act as agent
for the other for any purpose and shall not on behalf of the other enter into any contract, warranty, or representation as to
any matter. Neither shall be bound by the acts or conduct of the other.

 

Article
11 - Indemnity

 

		Sponsor
    shall indemnify, defend and hold harmless the University, its employees, officers and agents from any and all liability, loss,
    damage and expenses (including attorney fees) they may suffer as a result of claims, demands, costs, or judgments which may
    be made or instituted against them or any of them by reason of personal injury (including death) to any person or damage to
    property arising out of or connected with the performance of the activities to be carried out under the statement of work
    provided. Any such liability, loss or damage resulting from negligence or willful malfeasance by the University, its employees,
    officers and agents is excluded from this agreement to indemnify, defend and hold harmless.

 

Article
12 - Insurance

 

	12.1	University
                                         warrants and represents that University has adequate liability insurance, such protection
                                         being applicable to officers, employees, and agents while acting within the scope of
                                         their employment by University, and University has no liability insurance policy as such
                                         that can extend protection to any other person.
	 	 
	12.2	Each party hereby assumes any and all risks of personal
injury and property damage attributable to the negligent acts or omissions of that party and the officers, employees, and agents
thereof

 

 

Confidential materials omitted and filed separately
with the Securities and Exchange

Commission. Asterisks denote such omission.

    	 	5	 

     

    

BioSolar, Inc.
has requested that portions of this document be accorded confidential treatment pursuant

to Rule 24b-2 promulgated under the Securities
Exchange Act of 1934, as amended.

 

 

Article
13 - Assignment

 

	13.1	This Agreement shall not be assigned by either party
without the prior written consent of the Parties hereto.

 

Article
14 - Agreement Modification

 

	14.1	Any agreement to change the teens of this Agreement
in any way shall be valid only if the change is made in writing and approved by mutual agreement of authorized representatives
of the Parties hereto.

 

Article
15 - Notices

 

	15.	1 Notices, invoices, communications, and payments hereunder
shall be deemed made if given by registered or certified envelope, postage prepaid, and addressed to the party to receive such
notice, invoice, or communication at the address given below, or such other address as may hereafter be designated by notice in
writing:

 

	If
        to Sponsor:

        
	Dr.
        David Lee

        Chief
        Executive Officer

        BioSolar,

        27936
        Lost Canyon Road, Suite 202

        Santa
        Clarita, CA 91387

        Telephone:
        (661)251-0001; (818)679-5883 cell

        E-Mail:
        david@biosolar.corn 

        

 

	If
    to University:	Financial
    Transactions	Contract
    Information
	 	 	 
	 	Ms.
    Natalie Teagle	Dr.
                                         Mitzi Bond

	 	Telephone:
    (336) 285-3216	Telephone:
                                         (336) 285-3172

	 	E-Mail:
    ntteagle@ncat.edu	E-Mail:
    mbond@ncat.edu

 

 

Confidential materials omitted and filed separately
with the Securities and Exchange

Commission. Asterisks denote such omission. 

    	 	6	 

     

    

 BioSolar, Inc. has requested that
portions of this document be accorded confidential treatment pursuant

to Rule 24b-2 promulgated under the Securities Exchange
Act of 1934, as amended.

 

 

	If
Technical Matter:

        
	

Sungjin
Cho

Nanoengineering
Department

North
Carolina A&T State University

Telephone: (336)
285-2857

E-Mail:        schol@ncat.edu

        

 

	15.2	The State Auditor and North Carolina A&T State University's
internal auditors shall have access to persons and records as a result of all contracts or grants entered into by State agencies
or political subdivisions in accordance with General Statute 147-64.7 and Session Law 2010-194, Section 21 (i.e., the State Auditors
and internal auditors may audit the records of the contractor during the term of the contract to verify accounts and data affecting
fees or performance).

 

 

Confidential materials omitted and filed separately
with the Securities and Exchange

Commission. Asterisks denote such omission.

    	 	7	 

     

    

BioSolar,
Inc. has requested that portions of this document be accorded confidential treatment pursuant

to Rule 24b-2 promulgated under
the Securities Exchange Act of 1934, as amended.

 

 

IN
WITNESS WHEREOF, the Parties have caused this agreement to be executed as of the day and year first above written.

 

	BIOSOLAR,
    INC.	 	NORTH
    CAROLINA A&T STATE UNIV
	 	 	 	 	 
	/s/ David Lee	 	/s/ Barry L. Burks
	By:	David
    Lee	 	By:	Barry
    L. Burks
	Title:	Chief
    Executive Officer	 	Title:	Vice
    Chancellor for Research and Economic Development
	Date:	August
    16, 2016	 	Date:	August
    16, 2016

  

 

Confidential materials omitted and filed separately
with the Securities and Exchange

Commission. Asterisks denote such omission.

    	 	8	 

     

    

BioSolar, Inc. has requested that portions of this
document be accorded confidential treatment pursuant

 to Rule 24b-2 promulgated under the Securities Exchange Act of 1934, as amended.

 

 

Mutual
Non-disclosure Agreement

 

This
Agreement is effective August 16, 2016, by and between North Carolina Agricultural and Technical State University, having an address
at 1601 East Market Street, Greensboro, NC 27411 (hereinafter "N.C. A&T"), and BioSolar, Inc., having a place of
business at 27936 Lost Canyon Rd, Suite 202, Santa Clarita, CA 91387 and its representatives and affiliates.

 

Whereas,
COMPANY and N.C. A&T are interested in discussing exchanging and reviewing certain information, research areas of interest,
ideas/direction, applications, technologies, procedures, processes, devices, prototypes and/or the like regarding the following
topics: Silicon Alloy for High Energy and Power Anode Material

 

Now,
therefore, in consideration of the mutual exchange of information noted above and/or potential products in advance of others,
and in consideration of the promises, mutual covenants and other consideration, the receipt of which is hereby acknowledged, the
Parties agree as follows:

 

	1.	"INFORMATION"
                                         shall mean information, including but not limited to information or know-how relating
                                         to the Parties' research and development projects, business and financial information,
                                         trade secrets, and prototypes.

 

"CONFIDENTIAL
INFORMATION" shall mean any and all INFORMATION disclosed by the Parties in confidence regardless of whether disclosed such
INFORMATION in writing, orally or visually. All written or electronic CONFIDENTIAL INFORMATION shall be designated as such by
the transmitting/owning Party to the receiving Party in writing at the time of disclosure, pursuant to N.C.G.S. 132-1.2, or within
fifteen (15) business days of an oral or visual disclosure.

 

	2.	The
                                         Parties: (i) shall hold such CONFIDENTIAL INFORMATION in confidence; (ii) shall use such
                                         CONFIDENTIAL INFORMATION only for the purpose of providing COMPANY feedback and insight
                                         relating to its research and development projects; and (iii) shall not disclose such
                                         CONFIDENTIAL INFORMATION or the fact that such discussions are taking place to any third
                                         party.

 

These
restrictions on the use or disclosure of CONFIDENTIAL INFORMATION shall not apply to any CONFIDENTIAL INFORMATION which: (a) is
or becomes generally available to the public through no fault of the receiving Party; or (b) is hereinafter disclosed to the receiving
Party by a third party who has the right to disclose such CONFIDENTIAL INFORMATION; or (c) is in the possession of the receiving
Party in documentary form prior to the receipt of such CONFIDENTIAL INFORMATION from the transmitting Party; or (d) information
that must be disclosed by N.C. A&T pursuant to the North Carolina Public Records law.

 

	3.	No
                                         intellectual property rights resulting from any inventions, designs, drawings, abstracts,
                                         literary works, compilations, or other written material, and audiovisual works that arise
                                         from the INFORMATION that is exchanged between the Parties are conferred by either Party
                                         to the other Party under this Agreement.
	 	 
	4.	Upon
                                         termination or written request of COMPANY, or N.C. A&T, both Parties shall return
                                         all CONFIDENTIAL INFORMATION and copies thereof or certify in writing that the Parties
                                         have destroyed all CONFIDENTIAL INFORMATION and copies.
	 	 
	5.	The
                                         Parties acknowledge that unauthorized disclosure, use or sale of the CONFIDENTIAL INFORMATION,
                                         in whole or in part, or the disclosure, use or sale of any information or material created
                                         from, based upon or arising out of the CONFIDENTIAL INFORMATION may give rise to injury
                                         to the owning Party, for which either party may assert any rights or seek any remedies
                                         that may be available to the extent permitted by law. Nothing in this Agreement shall
                                         be construed as a waiver of sovereign immunity.

 

 

Confidential materials omitted and filed separately
with the Securities and Exchange

Commission. Asterisks denote such omission.

    	 	9	 

     

    

BioSolar, Inc. has requested that portions
of this document be accorded confidential treatment pursuant 

to Rule 24b-2 promulgated under the Securities Exchange Act of 1934,
as amended.

 

 

	6.	This
                                         Agreement shall expire three (3) years after the Effective Date unless terminated on
                                         thirty (30) days written notice by either Party.
	 	 
	7.	This
                                         Agreement constitutes the entire understanding between the parties hereto as to the subject
                                         matter herein and merges all prior discussions between them relating thereto. No amendment
                                         or modification of this Agreement shall be valid or binding on the parties unless made
                                         in writing and signed on behalf of each of the parties by their respective duly authorized
                                         officers or representatives.
	 	 
	8.	Receiving
                                         Party will not export, directly or indirectly, any technical data acquired from owning
                                         Party or any product utilizing any such data to any country for which the U.S. Government
                                         or any agency thereof at the time of export requires an export license or other governmental
                                         approval, without first obtaining such license or approval.
	 	 
	9.	This
                                         Agreement shall be governed by applicable federal laws and the local laws of the State
                                         of North Carolina, USA. The parties agree that the venue for any legal proceeding regarding
                                         enforcement of any of the provisions hereof shall be the State or Federal courts located
                                         in the State of North Carolina, USA.
	 	 
	10.	The
                                         rights and obligations of the parties under this Agreement may not be sold, assigned
                                         or otherwise transferred.
	 	 
	11.	Nothing
                                         in this Agreement shall be deemed to constitute either Party a partner, joint venture
                                         or employee of the other Party for any purpose.
	 	 
	12.	If
                                         a court finds any provision of this Agreement invalid or unenforceable, the remainder
                                         of this Agreement shall be interpreted so as best to affect the intent of the parties.

 

In
witness whereof, the parties have executed this Agreement on the respective dates entered below.

 

	North Carolina A&T State University	 	BioSolar, Inc.
	 	 	 	 	 
	By:	/s/ Dr. Barry L. Burks	 	By:	/s/ Dr. David
    Lee
	Name:	Dr.
Barry L. Burks	 	Name:	Dr.
    David Lee
	Title:	Vice Chancellor
    for Research & Economic Development	 	Title:	Chief Executive Officer
	Date:	August 16, 2016	 	Date:	August 16, 2016

 

The
undersigned acknowledge their responsibilities in maintaining the terms of this agreement:

 

	For
    North Carolina A&T State University	 	For
    COMPANY NAME
	 	 	 
	By:	 	By:
	Name:	 	Name:
	Title:	 	Title:
	Date:	 	Date:

  

 

 

Confidential materials omitted and filed separately
with the Securities and Exchange

Commission. Asterisks denote such omission.

 

10Exhibit 10.1

 

 

Executive Employment Agreement

 

ARIAD Pharmaceuticals, Inc. (the “Company”)
a Delaware corporation, and Elona Kogan (the “Employee”) enter into the
following Executive Employment Agreement as of the 15th day of July, 2016 (hereafter, the “Agreement”).

 

WHEREAS, the Company wishes to offer the
Employee employment according to the following terms and conditions;

 

WHEREAS, the Employee wishes to accept employment
with the Company on such terms; and

 

WHEREAS, the parties mutually intend that
this Agreement shall be the sole agreement between them concerning the Company’s employment of the Employee and the terms
and conditions of such employment.

 

NOW, THEREFORE, the Company and the Employee
agree as follows:

 

1.            Employment,
Duties and Acceptance.

 

1.1           The
Company hereby employs the Employee to render full-time services to the Company, and to perform such duties as the Company shall
reasonably direct Employee to perform. The Employee’s initial title shall be Senior Vice President, General Counsel, responsible
for legal operations, and Employee initially shall report directly to the Chief Executive Officer, unless and until the Chief Executive
Officer shall change such title or reporting relationship, in his or her sole discretion.

 

1.2           The
principal place of employment of the Employee hereunder shall be in the greater Boston, Massachusetts area. Employee acknowledges
that, from time to time, Employee may be required to provide services to the Company outside of the Boston, Massachusetts area.

 

1.3           Notwithstanding
anything to the contrary herein, although the Employee shall provide services as a full-time employee, it is understood that the
Employee may (a) have an academic appointment and (b) participate in professional activities (collectively, “Permitted
Activities”); provided, however, that such Permitted Activities do not interfere with the Employee’s
duties to the Company.

 

1.4           The
Employee represents and affirms that, as of the Effective Date (as defined in Section 2), Employee does not have any other contractual
obligations to any other Person that would prohibit or limit Employee’s employment with the Company or that would conflict
with the terms of this Agreement, except for the duty not to use or disclose another Person’s confidential information without
authorization.  Employee further acknowledges that the Company instructs Employee not to bring to the Company or use
or disclose in the course of Employee’s employment with the Company any confidential information belonging to another Person,
without that Person’s express authorization.

 

1.5           The
Employee acknowledges and agrees that employment with the Company and receipt of the payments, benefits, and other terms set forth
in this Agreement are contingent upon satisfactory completion and passing of the Company’s standard HR intake procedures,
including completion of an employment application and other new employee forms, authorization to work in the United States, background
check, verification of employment history, educational and professional licenses, degrees and/or credentials, and verification
of any other professional qualifications that Employee’s responsibilities at the Company may warrant.

 

    	 	1	 

     

    

 

Exhibit 10.1

 

 

2.            Term
of Employment.

 

The term of the Employee’s employment
under this Agreement shall commence on July 15, 2016 (the “Effective Date”), and shall end on December 31, 2018,
unless sooner terminated pursuant to Section 4 or 5 of this Agreement; provided, however, that this Agreement shall
automatically be renewed for successive one-year terms absent ninety (90) days written notice by either party to terminate the
Employee’s employment. The date on which the Employee’s employment ends, regardless of the reason for the termination,
shall be called the “Termination Date.”

 

3.            Compensation.

 

3.1           As
full compensation for all services to be rendered pursuant to this Agreement, the Company agrees to pay the Employee a base salary
at the fixed rate of $430,000 per year, and increased each year, by amounts, if any, to be determined by the Company, in its sole
discretion, payable in equal biweekly installments, less such deductions or amounts to be withheld as shall be required by applicable
law and regulations.

 

3.2           The
Employee shall be eligible to receive an annual discretionary bonus (“Discretionary Bonus”), in accordance with
the annual incentive program applicable generally to officers of the Company. The target for such Discretionary Bonus shall be
forty-five percent (45%) of the Employee’s annual base salary (“Discretionary Bonus Target”); provided
that the Company may elect to pay a greater or lesser bonus in any year, in its sole discretion, based on the assessment of Employee’s
individual performance objectives and the Company’s annual financial and operating objectives, performance, and other factors
as the Company may determine appropriate. Any Discretionary Bonus payable under this Section 3.2 shall be paid to the Employee
no later than March 15th of the year following the year in which such Discretionary Bonus is earned, and will be pro-rated
based on the number of days employed during the remainder of the calendar year following the Effective Date. Notwithstanding Sections
6.1 and 6.2, in order to receive the Discretionary Bonus, Employee must be employed by the Company on the date the Discretionary
Bonus is paid.

 

3.3           Subject
to the approval of the Compensation Committee and as soon as practicable following the Effective Date, the Company shall grant
the Employee in accordance with the Company’s equity incentive plan then in effect (the “Equity Plan”)
and the terms and conditions set forth in the Company’s customary award agreement:

 

3.3.1           Stock
options to purchase 200,000 shares of the Company’s common stock, with an exercise price equal to the fair market value of
the Company’s common stock on the date of grant.  The options shall be subject to a four-year vesting schedule,
vesting as to 25% of the shares on the first anniversary of the Effective Date and the remainder pro rata every three months thereafter
for 36 months.  Any portion of the option that is unvested as of the Termination Date shall be forfeited to the Company on
the Termination Date, except as set forth in Sections 6.1 and 6.2; and

 

3.3.2           Restricted
stock units for 100,000 shares of the Company’s common stock, which shall vest with respect to one-third of the shares of
the first, second and third anniversary of the Effective Date. The underlying shares of the Company’s common stock shall
be issued as soon as practicable following each vesting date. Unvested restricted stock units shall be forfeited to the Company
on the Termination Date, except as set forth in Sections 6.1 and 6.2.

 

3.4           The
Employee shall be eligible to participate in any incentive plan, stock-based compensation plan, bonus, deferred or extra compensation
plan, pension, group health, disability, long-term care, life, paid time off, insurance or other so-called “fringe”
benefits, which the Company provides for its executives at the comparable level. The terms of any such benefits will be governed
by the applicable plan documents and Company policies in effect from time to time.

 

    	 	2	 

     

    

 

Exhibit 10.1

 

 

3.5           In
accordance with the Company’s travel and expense policies in effect, the Company shall reimburse the Employee for all reasonable
travel and other expenses incurred by the Employee in connection with the performance of his or her duties and obligations under
this Agreement.

 

3.6           The
Employee agrees to abide by the Company’s Incentive Compensation Recoupment Policy and Stock Ownership Policy and such other
policies as the Company may adopt from time to time generally for senior executives.

 

3.7           Subject to prior written approval
by the Company, the Company shall pay or reimburse the following expenses that Employee may incur in connection with her relocation
to the greater Boston, Massachusetts area within twelve (12) months of the Effective Date: (a) the reasonable direct out-of-pocket
costs of transporting the Employee, the Employee’s immediate family and the Employee’s household items and two Motor
Vehicles from the Employee’s current residence to a new residence in the greater Boston, Massachusetts area, including storage
of such household items for a period of no more than twelve (12) months from the Effective Date; (b) the reasonable travel expenses
for the Employee related to travel to and from the greater Boston, Massachusetts area during the temporary housing period described
in the next clause, including up to two (2) trips for the Employee’s family; (c) the reasonable costs of rent and primary
services associated with temporary housing for the Employee and her family at an approved location in the greater Boston, Massachusetts
area for a period of no more than twelve (12) months from the Effective Date; and (d) except as described in the next succeeding
sentence, the reasonable closing costs associated with the Employee’s sale of her existing residence, so long as the sale
occurs before the first anniversary of the Effective Date, and purchase of a new residence in the greater Boston, Massachusetts
area, so long as the purchase takes place before the first anniversary of the Effective Date. The following closing costs will
not be paid by the Company: (i) real estate and other taxes; (ii) insurance premiums other than title insurance; (iii) brokerage
fees and commissions in connection with the purchase of a new residence; and (iv) commitment fees and prepaid interest (i.e., “points”)
in excess of two percent (2%). Should Employee leave the Company before the first anniversary of the Effective Date all relocation
monies used must be paid back to the Company.

 

3.8           To
facilitate the Employee’s transition to the Company, the Company shall provide the Employee with a one-time transition advance
(the “Advance”) in the gross amount of $100,000, less such deductions or amounts to be withheld as shall be
required by applicable law and regulations, payable as follows: fifty percent (50%) in the next regularly scheduled payroll following
thirty (30) days after the Effective Date and the remaining fifty percent (50%) in the regularly scheduled payroll six (6) months
after the Effective Date. Notwithstanding the foregoing, (i) if the Employee terminates her employment before the second anniversary
of the Effective Date, except as provided pursuant to Section 5.1(a) herein, or (ii) the Company terminates Employee’s employment
for Cause at any time pursuant to Section 4.1(c) herein, then the Employee shall be obligated to repay the Advance within thirty
(30) days of such termination. If the Employee remains employed with the Company in good standing as of the second anniversary
of the Effective Date, then the Advance shall no longer be subject to repayment by the Employee.

 

4.            Termination
by the Company.

 

4.1           The
Company may terminate the Employee’s employment at any time upon the occurrence of any of the following:

 

(a)          The
Employee shall die while employed by the Company.

 

(b)          The
Employee shall become physically or mentally disabled, whether totally or partially, so that the Employee is unable substantially
to perform his or her services 

 

    	 	3	 

     

    

 

Exhibit 10.1

 

 

hereunder for (i) a period of one-hundred eighty (180) consecutive days, or (ii) for shorter periods
aggregating one-hundred eighty (180) days during any twelve (12) month period.

 

(c)          The
Employee acts in a manner that provides Cause for termination, as determined in the sole discretion of the Company. If the conduct
constituting Cause hereunder is susceptible to cure, the Company shall provide the Employee written notice of termination pursuant
to this Section 4, and Employee shall have thirty (30) days to cure or remedy such failure or breach, in which case Employee’s
employment shall not be terminated.  If the conduct is not susceptible to cure as determined by the Company in its sole
discretion, the Employee’s employment shall terminate upon written notice by the Company.

 

(d)          The
Company elects to terminate the Employee’s employment not due to the death or disability of the Employee or in circumstances
not constituting Cause. The Company shall provide thirty (30) days’ notice of such termination, provided, however, that Company
may elect to pay Employee in lieu of providing notice.

 

5.            Termination
by the Employee.

 

5.1           The
Employee may terminate Employee’s employment, within thirty (30) days of the initial occurrence of either of the following:

 

(a)          A
material breach of the terms of this Agreement by the Company and such breach continues for thirty (30) days after the Employee
gives the Company written notice of such breach and an opportunity to cure it.

 

(b)          The
Employee elects to terminate the Employee’s employment in all other circumstances not constituting a material breach that
is not cured by the Company (as set forth in Section 5.1(a)).

 

6.            Compensation
on Termination.

 

6.1           Termination
by the Company Pursuant to Section 4.1(d) or by the Employee Pursuant to Section 5.1(a). If the Employee executes a separation
agreement and release of claims in the Company’s standard form (the “Separation Agreement”) and (i) the
Company terminates the Employee’s employment pursuant to Section 4.1(d) or (ii) the Employee terminates Employee’s
employment pursuant to Section 5.1(a), then, subject to compliance with Sections 7, 8, and 9 below: (1) the Company shall continue
to pay Employee’s then-current base salary for the period of twelve (12) months (the “Severance Period”);
(2) the Company shall pay the Employee an amount equal to any earned and accrued but unpaid Discretionary Bonus for the prior fiscal
year which has not been previously paid; (3) all equity awards outstanding as of the Termination Date except for performance awards
for which the performance has not yet been achieved as of the Termination Date shall vest as of the Termination Date to the extent
that the equity award would have vested during the Severance Period; the remainder of the unvested equity awards and performance
awards shall be forfeited on the Termination Date; and (4) the Company shall continue to pay its share of the costs for Employee’s
coverage under the Company’s group health insurance plan for twelve (12) months from the Termination Date (the “COBRA
Continuation Period”), provided Employee makes an effective COBRA election regarding group health insurance.  Except
as otherwise required under Section 13.2, all monetary payments referenced in this Section 6.1 shall be paid in equal installments
over the course of the Severance Period beginning on the first regular pay date following the effective date of the Separation
Agreement.  The Employee will not be eligible for any payments or benefits under the following Section 6.2, if Employee
is eligible to receive payments and benefits under this Section 6.1; provided, however, that if Employee commences receiving payments
and benefits under this Section 6.1 and a Change in Control occurs within three (3) months of the Termination Date, the Company
shall pay Employee the 

 

    	 	4	 

     

    

 

Exhibit 10.1

 

 

payments and benefits set forth in Section 6.2, less any payments and benefits received to date by the Employee
under this Section 6.1. If Employee obtains alternate group health insurance benefits during the COBRA Continuation Period, Employee
shall immediately notify Company in writing and Company shall no longer be obligated to pay its share of the costs for continuing
Employee’s coverage under the Company’s group health insurance plan.

 

6.2           Termination
in the Event of a Change in Control. In the event of a consummation of a Change in Control of the Company, and if, upon such
occurrence or within the period of one (1) year following such occurrence or three (3) months before a Change in Control, (i) the
Company provides notice of non-renewal pursuant to Section 2, the Company terminates the Employee’s employment pursuant to
Section 4.1(d), or the Employee resigns for Good Reason, and (ii) the Employee executes a Separation Agreement, then, subject to
compliance with Sections 7, 8, and 9 below: (1) the Company shall pay Employee an amount equal to two (2) times the sum of the
Employee’s then-current base salary and Discretionary Bonus Target; (2) the Company shall pay the Employee an amount equal
to any earned and accrued but unpaid Discretionary Bonus for the prior fiscal year which has not been previously paid; (3) all
equity awards outstanding as of the Termination Date shall vest in full, except for performance awards for which the performance
has not been achieved as of the Termination Date; (4) all performance awards outstanding as of the Termination Date for which performance
has not been achieved shall be deemed earned as of the Termination Date at the greater of actual performance or target and shall
vest on the Termination Date as to the number of shares earned; and (5) the Company shall continue to pay its share of the costs
for Employee’s coverage under the Company’s group health insurance plan for a period of eighteen (18) months (the “Change
in Control COBRA Continuation Period”), provided Employee makes an effective COBRA election regarding group health insurance.  Except
as otherwise required under Section 13.2, all monetary payments referenced in this Section 6.2 shall be made in a lump sum on the
first regularly scheduled payroll following the effective date of the Separation Agreement.  If Employee obtains alternate
group health insurance benefits during the Change in Control COBRA Continuation Period, Employee shall immediately notify Company
in writing and Company shall no longer be obligated to pay its share of the costs for continuing Employee’s coverage under
the Company’s group health insurance plan. Notwithstanding the foregoing in the event the equity awards are not assumed or
substituted and are cancelled in connection with a Change in Control without the substitution of a cash payment all equity awards
shall vest in full immediately prior to the Change in Control (and the performance awards shall be deemed vested and earned as
to the number of shares set forth in (4) above).

 

6.3           All
Other Terminations. If the Company terminates Employee’s employment due to the death or disability of the Employee or
for Cause pursuant to Sections 4.1(a), (b) or (c) or the Employee terminates Employee’s employment pursuant to Section 5.1(b),
Employee shall only receive payment for all earned and/or vested benefits and wages pursuant to the terms of the underlying benefit
plans and programs and all applicable laws through the Termination Date, and Employee shall not be entitled to any of the other
payments and benefits set forth in Sections 6.1 or 6.2.

 

7.            Confidentiality.

 

7.1           The
Employee acknowledges that, during the course of performing Employee’s services hereunder, the Company shall disclose to
Employee Confidential Information.  

 

7.2           The
Employee acknowledges that the Company’s business is extremely competitive, dependent in part upon the maintenance of secrecy,
and that any disclosure of Confidential Information would result in serious irreparable harm to the Company.

 

7.3           The
Employee agrees that Confidential Information only shall be used by the Employee in connection with Employee’s activities
hereunder as an employee of the Company, and shall not be used in any way that is detrimental to the Company.

 

    	 	5	 

     

    

 

Exhibit 10.1

 

 

7.4           The
Employee agrees not to disclose, directly or indirectly, any Confidential Information to any third Person, other than representatives
or agents of the Company.  

 

7.5           The
Employee may disclose any Confidential Information that is required to be disclosed by law, government regulation or court order.  If
disclosure is required, the Employee shall give the Company advance notice so that the Company may seek a protective order or take
other action reasonable in light of the circumstances. Additionally, the Employee may disclose a Company trade secret in confidence
to an attorney or federal, state or local government official solely for the purpose of reporting or investigating a suspected
violation of law or in a filing in a lawsuit made under seal consistent with the Company’s Standard Operating Procedure on
Compliance Violations.

 

7.6           Upon
termination of Employee’s employment, regardless of the reason for termination, the Employee shall promptly return to the
Company all materials, whether in electronic or hardcopy format, containing Confidential Information, as well as data, records,
reports and other property, furnished by the Company to the Employee or produced by the Employee in connection with services rendered
hereunder.

 

7.7           The
terms of this Section 7 are in addition to, and not in lieu of, any statutory or other contractual or legal obligation that Employee
may have relating to the protection of the Company’s Confidential Information.

 

7.8           The
Employee shall continue to be bound by the terms of the confidentiality provisions contained in this Section 7 following the termination
of Employee’s employment, regardless of the reason for termination.

 

8.            Inventions
Discovered by the Employee While Performing Services Hereunder.

 

8.1           During
Employee’s employment with the Company, the Employee shall promptly disclose to the Company any Inventions, whether patentable,
copyrightable or not, made, conceived, developed or first reduced to practice by the Employee, either alone or jointly with others,
while performing services for the Company. Without limiting the foregoing, Employee also acknowledges that all original works of
authorship which are made by Employee (solely or jointly with others) within the scope of the Employee’s employment or which
relate to the business of the Company and which are protectable by copyright are “works made for hire” pursuant to
the United States Copyright Act (17 U.S.C. § 101). Employee hereby assigns to the Company all of Employee’s right, title
and interest in and to any such Inventions.  During and after the Employee’s employment with the Company, the Employee
shall execute any documents necessary to perfect the assignment of such Inventions to the Company and to enable the Company to
apply for, obtain, and enforce patents and copyrights in any and all countries on such Inventions. The Employee hereby irrevocably
designates the Chief Intellectual Property Officer of the Company, or other person performing such function, as Employee’s
agent and attorney-in-fact to execute and file any such document and to do all lawful acts necessary to apply for and obtain patents
and copyrights and to enforce the Company’s rights under this paragraph.

 

8.2           With
respect to any Inventions, and work of any similar nature (from any source), whenever created, which Employee has not conceived,
reduced to practice or developed during the period while Employee is performing services for the Company, but which Employee provides
to the Company or incorporates in any Company product or system, Employee hereby grants to the Company a royalty-free, fully paid-up,
non-exclusive, perpetual and irrevocable license throughout the world to use, modify, create derivative works from, disclose, publish,
translate, reproduce, deliver, perform, sell, license, dispose of, and to authorize others so to do, all such Inventions. Employee
shall not include in any Inventions Employee delivers to the Company or uses on its behalf, without the prior written approval
of the Company, any material which is or shall be patented, copyrighted or trademarked by

 

    	 	6	 

     

    

 

Exhibit 10.1

 

 

Employee or others unless Employee provides
the Company with the written permission of the holder of any patent, copyright or trademark owner for the Company to use such material
in a manner consistent with then-current Company policy.

 

8.3           This
Section 8 shall survive the termination of Employee’s employment, regardless of the reason for termination.

 

9.            Non-Competition
and Non-Solicitation.

 

During the Employee’s employment with
the Company and for a period of one (1) year following the Termination Date: (a) the Employee shall not in the United States or
in any country in which the Company shall then be doing business, directly or indirectly, enter the employ of, or render any services
to, any person, firm or corporation engaged in any business that is Competing with the business of the Company or of any of its
Subsidiaries or Affiliates of which the Employee may become an employee or officer during the Employee’s employment with
the Company; Employee shall not engage in such business on Employee’s own account; and Employee shall not become interested
in any such business, directly or indirectly, as an individual, partner, shareholder, director, officer, principal, agent, employee,
trustee, consultant, or any other relationship or capacity; provided, however, that nothing contained in this Section 9 shall be
deemed to prohibit the Employee from acquiring, solely as an investment, up to two percent (2%) of the shares of capital stock
of any Competing public corporation or from being employed by or associated with (including serving as a consultant to) a subsidiary,
division, department, unit or affiliate (each, a “Unit”) of an entity if that Unit is not engaged in any business
which is Competing with the business of the Company, irrespective of whether some other Unit of such entity engages in such competition;
and (b) the Employee nor any Affiliate of the Employee shall not, directly or indirectly, solicit, entice or persuade, or attempt
to solicit, entice or persuade, any directors, key advisors, officers or employees of or consultants to the Company (collectively,
“Associates of the Company”) to leave the services of the Company for any reason.  This non-solicitation
provision shall not apply to Associates of the Company who previously terminated their relationship with the Company. The above
covenants will apply to the Employee, regardless of the circumstances under which the employment ends.

 

9.1           If
the Employee commits a breach, or threatens to commit a breach, of any of the provisions of this Section 9, the Company shall have
the following rights and remedies:

 

9.1.1           The
right and remedy to have the provisions of this Agreement specifically enforced by any court having equity jurisdiction, it being
acknowledged and agreed that any such breach or threatened breach shall cause irreparable injury to the Company and that money
damages shall not provide an adequate remedy to the Company; and

 

9.1.2           The
right and remedy immediately to cease providing the salary continuation payments and other benefits under Sections 6.1 and 6.2
of this Agreement and to require the Employee to repay to the Company any such payments and benefits that already have been provided
as of the time the Company learns of Employee’s breach of this Section 9; provided, however, that if the Employee challenges
pursuant to Section 12.2 the Company’s enforcement of the provisions of Section 9 and the cessation of salary continuation
payments and other benefits under this Section 9.1.2 and the Employee prevails in such action, the Company shall pay the Employee
any salary continuation payments and other benefits that were withheld.

 

9.1.3           The
right and remedy and to require the Employee to account for and pay over to the Company all compensation, profits, monies, accruals,
increments or other benefits (collectively “Benefits”) derived or received by the Employee as the result of
any transactions constituting a breach of any of the provisions of the preceding paragraph, and the Employee hereby agrees to account
for and pay over such Benefits to the Company.

 

    	 	7	 

     

    

 

Exhibit 10.1

 

 

9.1.4           The
one (1) year post-termination restriction period shall be tolled during any period of such breach or threatened breach.

 

Each of the rights and remedies enumerated
above shall be independent of the other, and shall be severally enforceable, and all of such rights and remedies shall be in addition
to, and not in lieu of, any other rights and remedies available to the Company under law or in equity.

 

9.2           If
any of the covenants contained in Section 7, 8 or 9, or any part thereof, is hereafter construed to be invalid or unenforceable,
the same shall not affect the remainder of the covenant or covenants, which shall be given full effect without regard to the invalid
portions.

 

9.3           If
any of the covenants contained in Section 7, 8 or 9, or any part thereof, is held to be unenforceable because of the duration of
such provision or the area covered thereby, the parties agree that the court making such determination shall have the power to
reduce the duration and/or area of such provision and, in its reduced form, such provision shall then be enforceable.

 

9.4           The
covenants in Sections 7, 8, and 9 are conditions of Employee’s employment with the Company, and they are not tied to Employee’s
performance of any particular position, role or job; therefore, the covenants in Sections 7, 8, and 9 shall survive any change
in Employee’s position, title, compensation, benefits, role, or responsibilities and shall remain in full force and effect
following any such change.

 

10.           Indemnification.

 

The Company shall indemnify the Employee,
to the maximum extent permitted by applicable law, against all costs, charges and expenses incurred or sustained by Employee in
connection with any action, suit or proceeding to which Employee may be made a party by reason of being an officer, director or
employee of the Company or of any Subsidiary or Affiliate of the Company. The Company shall provide at its expense, subject to
its availability upon reasonable terms, directors and officers insurance for the Employee in reasonable amounts. The Company shall
make, in its sole discretion, determination with respect to (a) the availability of insurance upon reasonable terms and (b) the
amount of such insurance coverage.

 

11.           Notices.

 

All notices, requests, consents and other
communications required or permitted to be given hereunder shall be in writing and shall be deemed to have been duly given if sent
by facsimile (delivery confirmed by such service), private overnight mail service (delivery confirmed by such service), registered
or certified mail (return receipt requested), electronic mail (upon confirmation of receipt) or delivered personally, as follows
(or to such other address as either party shall designate by notice in writing to the other in accordance herewith):

 

If to the Company:

 

ARIAD Pharmaceuticals, Inc.

26 Landsdowne Street

Cambridge, Massachusetts 02139

Attention: General Counsel

Telephone: (617) 494-0400

Fax: (617) 494-1828

Email:

 

    	 	8	 

     

    

 

Exhibit 10.1

 

 

If to the Employee:

 

Elona Kogan

26 Landsdowne Street

Cambridge, MA 02139

Telephone:

Email:

 

12.           General.

 

12.1         This
Agreement shall be governed by and construed and enforced in accordance with the laws of the Commonwealth of Massachusetts.

 

12.2         Other
than actions for injunctive relief, including a civil seizure order under the Defend Trade Secrets Act, all disputes arising out
Employee’s employment with the Company and/or this Agreement must be submitted for resolution by mandatory, binding arbitration
under the Federal Arbitration Act. Binding confidential and private arbitration under this Agreement shall be conducted before
a neutral arbitrator selected by both parties from JAMS in Boston, Massachusetts. A request for arbitration must be submitted within
the appropriate statute of limitations period under Massachusetts law. After a request for arbitration is submitted, the parties
will promptly select a date or dates for arbitration. Thereafter, JAMS administration will give to the parties the names of five
arbitrators who are qualified, not conflicted, and can hear the matter on the date(s) selected. Each party will independently rank
each arbitrator from one to five, with one representing the most desirable arbitrator and five representing the least desirable
arbitrator, and will forward such ranking to JAMS administration confidentially. JAMS will then select the arbitrator with the
highest combined rank. Where the dispute proceeds to actual arbitration, the Employee and the Company agree: (i) to engage in a
one-day arbitration; (ii) to exchange documents in advance of such arbitration; and (iii) to limit each party to one (1) deposition
at the arbitration. For all disputes arbitrated in this manner, the Arbitrator shall, within thirty (30) days after the conclusion
of the arbitration, issue a brief written opinion setting forth the factual and legal findings and conclusions on which his or
her decision is based. The Arbitrator will be empowered to award either party any remedy at law or equity that the party would
otherwise have been entitled to had the matter been litigated in court including, but not limited to, general, special, and punitive
damages, injunctive relief, costs and attorney’s fees; provided, however, that the authority to award any remedy is subject
to whatever limitations, if any, exist in the applicable law on such remedies. The Arbitrator shall have no jurisdiction to issue
any award contrary to or inconsistent with the law, including the statute at issue.

 

12.3         The
Section headings contained herein are for reference purposes only and shall not in any way affect the meaning or interpretation
of this Agreement.

 

12.4         This
Agreement sets forth the entire agreement and understanding of the parties relating to the subject matter hereof, and supersedes
all prior agreements, arrangements and understandings, written or oral, relating to the subject matter hereof. Neither party has
made any representation, promise or inducement that is not embodied in this Agreement, and neither party shall be bound by or liable
for any alleged representation, promise or inducement not so set forth.

 

12.5         The
provisions hereof shall inure to the benefit of, and be binding upon and assignable to, successors of the Company by way of merger,
consolidation or sale. The Employee may not assign or delegate to any third person the Employee’s obligations under this
Agreement. The rights and benefits of the Employee under this Agreement are personal to the Employee and no such right or benefit
shall be subject to voluntary or involuntary alienation, assignment or transfer. The Company shall require any successor (whether
direct or indirect, by purchase, merger, consolidation or otherwise)

 

    	 	9	 

     

    

 

Exhibit 10.1

 

 

 to all or substantially all of the business and/or assets
of the Company expressly to assume and agree to perform this Agreement in the same manner and to the same extent that the Company
would have been required to perform it if no such succession had taken place. As used in this Agreement, “the Company”
shall mean both the Company as defined above and any such successor that assumes and agrees to perform this Agreement, by operation
of law or otherwise.

 

12.6         This
Agreement may be amended, modified, superseded, canceled, renewed or extended, and the terms or covenants hereof may be waived
only by a written instrument executed by the parties hereto or in the case of a waiver, by the party waiving compliance. In order
to be effective, any such modification or amendment must be signed by the Company’s Chief Executive Officer; Employee acknowledges
that no other officer, employee, director or representative is authorized to modify or amend the terms of this Agreement. The failure
of a party at any time or times to require performance of any provision hereof shall in no manner affect the right at a later time
to enforce the same. No waiver by a party of the breach of any term or covenant contained in this Agreement, whether by conduct
or otherwise, in any one or more instances, shall be deemed to be, or construed as, a further or continuing waiver of any such
breach, or a waiver of the breach of any other term or covenant contained in this Agreement.

 

12.7         During
and after Employee’s employment, Employee shall cooperate fully with the Company in the defense or prosecution of any claims
or actions now in existence or which may be brought in the future against or on behalf of the Company which relate to events or
occurrences that transpired while Employee was employed by the Company. Employee’s full cooperation in connection with such
claims or actions shall include, but not be limited to, being available to meet with counsel to prepare for discovery or trial
and to act as a witness on behalf of the Company at mutually convenient times. During and after Employee’s employment, Employee
also shall cooperate fully with the Company in connection with any investigation or review of any federal, state or local regulatory
authority as any such investigation or review relates to events or occurrences that transpired while Employee was employed by the
Company. The Company shall reimburse Employee for any reasonable out-of-pocket expenses incurred in connection with the Employee’s
performance of obligations pursuant to this Section 12.7.

 

13.           Section
409A.

 

13.1         Notwithstanding
any other provision to the contrary, the parties agree that amounts payable under the Agreement shall be interpreted to comply
with or be exempt from Section 409A of the Internal Revenue Code of 1986, as amended, and the final regulations and any guidance
promulgated thereunder (“Section 409A”) consistent with the intentions set forth in this Section 13.

 

13.2         Salary
continuation payments that may become payable under either Section 6.1 or Section 6.2 are intended to be exempt from Section 409A
to the maximum extent permitted under (a) the “short-term deferral” rule set forth in Section 1.409A-1(b)(4) of the
Treasury Regulations (to the extent of such payments made from the Termination Date, as the case may be, through March 14th of
the calendar year following such separation) and (b) the “separation pay due to involuntary separation from service”
rule set forth in Section l.409A--1(b)(9)(iii) of the Treasury Regulations (to the extent that such payments made after said
March 14th). For purposes of the Agreement, each payable and benefit payable hereunder is intended to constitute a separate payment
for purposes of Section 1.409A-2(b)(2) of the Treasury Regulations.

 

13.3         Continued
Company-paid COBRA benefits described in Section 6.1 and 6.2 are intended to be exempt from Section 409A under either the welfare
benefits exception set forth in Section 1.409A-1(a)(5) of the Treasury Regulations (if COBRA premium payments are not taxable to
the 

 

    	 	10	 

     

    

 

Exhibit 10.1

 

 

Employee) or the limited payments exception set forth in Section 1.409A-1(b)(9)(v)(D) of the Treasury Regulations (if COBRA
premium payments are taxable to the Employee).

 

13.4         All
expenses or other reimbursements as provided under the Agreement shall be payable in accordance with the Company’s policies
in effect from time to time, but in any event shall be made on or prior to the last day of the taxable year following the taxable
year in which such expenses were incurred by the Employee. No reimbursement or expenses eligible for reimbursement in any taxable
year shall in any way affect the expenses eligible for reimbursement in any other taxable year and the right to reimbursement
or in-kind benefits shall not be subject to liquidation or exchanged for another benefit.

 

13.5         If
the Employee is considered by the Company to be a “specified employee” (within the meaning of Section 409A) upon separation
from service and any payment or the provision of any benefit under the Agreement or otherwise that is payable upon separation from
service is determined to be nonqualified deferred compensation subject to Section 409A after giving full effect to the intentions
set forth in this Section 13, then any such payment or benefit shall not commence until the earlier of (i) the first payroll period
commencing during the seventh month immediately following the date of such separation from service, and (ii) the date of Employee’s
death (the “Delay Period”). Upon the expiration of the Delay Period, all payments and benefits delayed hereunder
(whether they would have otherwise been payable in a single sum or in installments in the absence of such delay) shall be paid
or reimbursed to Employee in a lump sum, and any remaining payments and benefits due under the Agreement shall be paid or provided
in accordance with the normal payment dates specified for them herein.

 

13.6         All
payments and benefits that are payable upon the termination of the Employee’s employment hereunder shall be paid or provided
only upon the Employee’s “separation from service” from the Company within the meaning of Section 409A (determined
after applying the presumptions set forth in Section 1.409A-1(h)(1) of the Treasury Regulations.

 

14.           Section
280G.

 

14.1         The
Employee shall bear all expense of, and be solely responsible for, all federal, state, local or foreign taxes due with respect
to any payment received under the Agreement, including, without limitation, any excise tax imposed by Section 4999 of the Code
(the “Excise Tax”); provided, however, that any payment or benefit received or to be received
by the Employee in connection with a Change in Control or the termination of employment (whether payable under the terms of the
Agreement or any other plan, arrangement or agreement with the Company or an Affiliate (collectively, the “Payments”)
that would constitute a “parachute payment” within the meaning of Section 280G of the Code, shall be reduced to the
extent necessary so that no portion thereof shall be subject to the Excise Tax but only if, by reason of such reduction, the net
after-tax benefit received by the Employee shall exceed the net after-tax benefit that would be received by the Employee if no
such reduction was made.  For purposes of this Section 14:

 

(a)          The
“net after-tax benefit” shall mean (i) the Payments which the Employee receives or is then entitled to receive from
the Company or its Affiliates that would constitute “parachute payments” within the meaning of Section 280G of the
Code, less (ii) the amount of all federal, state and local income and employment taxes payable by the Employee with respect to
the foregoing calculated at the highest marginal income tax rate for each year in which the foregoing shall be paid to the Employee
(based on the rate in effect for such year as set forth in the Code as in effect at the time of the first payment of the foregoing),
less (iii) the amount of Excise Tax imposed with respect to the payments and benefits described in (i) above.

 

    	 	11	 

     

    

 

Exhibit 10.1

 

 

(b)          All
determinations under this Section 14 will be made by an accounting firm or law firm that is selected for this purpose by the Company
prior to the Change in Control (the “280G Firm”).  All fees and expenses of the 280G Firm shall be
borne by the Company. The Company will direct the 280G Firm to submit any determination it makes under this Section 14 and detailed
supporting calculations to both the Employee and the Company as soon as reasonably practicable.

 

(c)          If
the 280G Firm determines that one or more reductions are required under Section 14, the 280G Firm shall also determine which Payments
shall be reduced (first from cash payments and then from non-cash benefits) to the extent necessary so that no portion thereof
shall be subject to the excise tax imposed by Section 4999 of the Code, and the Company shall pay such reduced amount to the Employee.
The 280G Firm shall make reductions required under this Section 14 in a manner that maximizes the net after-tax amount payable
to the Employee.

 

(d)          As
a result of the uncertainty in the application of Section 280G at the time that the 280G Firm makes its determinations under this
Section 14, it is possible that amounts will have been paid or distributed to the Employee that should not have been paid or distributed
(collectively, the “Overpayments”), or that additional amounts should be paid or distributed to the Employee
(collectively, the “Underpayments”).  If the 280G Firm determines, based on either the assertion of
a deficiency by the Internal Revenue Service against the Company or the Employee, which assertion the 280G Firm believes has a
high probability of success or controlling precedent or substantial authority, that an Overpayment has been made, the Employee
must repay to the Company, without interest; provided, however, that no loan will be deemed to have been made and no amount will
be payable by the Employee to the Company unless, and then only to the extent that, the deemed loan and payment would either reduce
the amount on which the Employee is subject to tax under Section 4999 of the Code or generate a refund of tax imposed under Section
4999 of the Code. If the 280G determines, based upon controlling precedent or substantial authority, that an Underpayment has occurred,
the 280G Firm will notify the Employee and the Company of that determination, and the Company will promptly pay the amount of that
Underpayment to the Employee.

 

(e)          The
parties will provide the 280G Firm access to and copies of any books, records, and documents in their possession as reasonably
requested by the 280G Firm, and otherwise cooperate with the 280G Firm in connection with the preparation and issuance of the determinations
and calculations contemplated by this Section 14.

 

15.           Definitions.
As used herein the following terms have the following meaning:

 

(a)          “Affiliate”
means and includes any corporation or other business entity controlling, controlled by or under common control with the corporation
in question.

 

(b)          “Cause”
means any of the following: (i) the failure by the Employee to perform any of Employee’s material duties hereunder; (ii)
the conviction of the Employee of any felony; (iii) the commission by the Employee of any crime relating to Employee’s employment
with the Company; (iv) willful misconduct by the Employee that has resulted, and could reasonably have been expected to result,
in significant harm to the Company’s business or reputation; (v) the failure by the Employee to materially comply with the
written policies of the Company; or (vi) a material breach of the terms of this Agreement by the Employee (including, without limitation,
a breach of Section 1.4, a failure to commence employment or actions taken by the Employee which create a conflict of interest
for the Employee between the Company or any of its Affiliates, on the one hand, and a competitor of the Company or any of its Affiliates,
on the other hand).  

 

(c)          “Change
in Control” means the occurrence of any of the following events: (i) if any “Person” (as such term is used
in Sections 13(d) and 14(d) of the Securities 

 

    	 	12	 

     

    

 

Exhibit 10.1

 

 

Exchange
Act of 1934, as amended) becomes the “Beneficial Owner” (as defined in Rule 13d-3 under said Act), directly
or indirectly, of securities of Company representing 50% or more of the total voting power represented by Company’s then
outstanding voting securities (excluding for this purpose Company or its Affiliates or any employee benefit plan of Company);
(ii) a merger or consolidation of Company, whether or not approved by the Company’s Board of Directors, other than a merger
or consolidation which would result in the voting securities of Company outstanding immediately prior thereto continuing to represent
(either by remaining outstanding or by being converted into voting securities of the surviving entity or the parent of such corporation)
more than fifty percent (50%) of the total voting power represented by the voting securities of Company or such surviving entity or
parent of such corporation outstanding immediately after such merger or consolidation; or (iii) the sale or disposition by Company
of all or substantially all of Company’s assets in a transaction requiring stockholder approval.

 

(d)          “Competing”
means commercializing or developing in Phase 2 clinical trials or later a drug or drug candidate for the same disease that is then
being commercialized or developed in Phase 2 clinical trials or later by the Company or of any of its Subsidiaries or Affiliates
prior to any Change in Control.

 

(e)          “Confidential
Information” means trade secrets and confidential and proprietary information of the Company, or any information provided
to the Employee or the Company under an obligation of confidentiality to a third party, or any confidential, trade secret, or proprietary
information acquired by the Company from others with whom the Company or any Affiliate has a business relationship, whether in
written, oral, electronic or other form, including, but not limited to, technical data and specifications, structures, cloning
vectors, nucleic acid sequences, proteins, protein domains, organisms, cell lines and other biological materials, business and
financial information, product and marketing plans, customer and client information, customer and client lists, customer, client
and vendor identities and characteristics, agreements, marketing knowledge and information, sales figures, pricing information,
marketing plans, business plans, strategy forecasts, financial information, budgets, software, projections and procedures, the
confidential evaluation of (and confidential use or non-use by the Company or any Affiliate of) technical or business information
in the public domain, Inventions, and any other scientific, technical or trade secrets of the Company or of any third party provided
to Employee or the Company under a condition of confidentiality.1/
The term “Confidential Information” does not include information that (a) is or becomes generally available to the
public other than by disclosure in violation of this Agreement, (b) was within the Employee’s possession prior to being furnished
to the Employee, (c) becomes available to the Employee on a nonconfidential basis or (d) was independently developed by the Employee
without reference to the information provided by the Company.

 

(f)          “Good
Reason” means the occurrence of one or more of the following conditions arising without the Employee’s voluntary
consent:

 

(i)          Any
requirement that the Employee relocate to a worksite that would increase the Employee’s one-way commuting distance by more
than twenty-five (25) miles;

 

 

 

1/The term “trade secrets,” as used
in this Agreement, shall be given its broadest possible interpretation under applicable law and shall mean all forms and types
of financial, business, scientific, technical, economic, or engineering information, including patterns, plans, compilations, program
devices, formulas, designs, prototypes, methods, techniques, processes, procedures, programs, or codes, whether tangible or intangible,
and whether or how stored, compiled, or memorialized physically, electronically, graphically, photographically, or in writing that
(1) the Company has taken reasonable measures to keep secret, and that (2) derives independent economic value, actual or potential,
from not being generally known to, and not being readily ascertainable through proper means by, another person who can obtain economic
value from the disclosure or use of the information.

 

    	 	13	 

     

    

 

Exhibit 10.1

 

 

(ii)         The
Company’s material breach of any provision of this Agreement, provided that the Employee gives notice to the Company within
thirty (30) days of the initial occurrence of the breach and it is not cured within thirty (30) days of such notice. A “material
breach of any provision of this Agreement” under this clause (ii) includes, without limitation, the Company’s failure
to pay or provide salary, bonus or any other form of compensation referenced in Section 3 that is not corrected by the Company
within thirty (30) days after receiving notice from the Employee, provided such notice is provided by the Employee within thirty
(30) days of the initial occurrence of the breach; provided, further, however, that across the board reductions in compensation
or benefits affecting similarly situated employees shall not constitute a material breach of this Agreement or Good Reason;

 

(iii)        The
material diminution of Employee’s roles, responsibilities or scope of authority in the Company and/or the entity resulting
from a Change in Control, provided that the Employee gives notice to the Company within thirty (30) days of the initial occurrence
of the material diminution, and it is not cured within thirty (30) days of such notice; provided, further, however, that it shall
not constitute Good Reason that a Change in Control results in Employee working for a subsidiary or operating division of a larger
organization, provided that Employee’s roles, responsibilities and scope of authority within that subsidiary or operating
division are comparable to Employee’s roles, responsibilities and scope of authority with the Company prior to the Change
in Control.  

 

This definition of “Good Reason” shall be interpreted
consistent with the definition of an “involuntary separation from service” under Section 1.409A-1 (n) of the Treasury
Regulations.

 

(g)          “Inventions”
means any process, ideas, discoveries, creations, manuscripts and properties, innovations, improvements, know-how, inventions,
designs, developments, apparatus, techniques, methods, laboratory notebooks, formulae, writings, specifications, sound recordings,
and pictorial and graphical representations.

 

(h)          “Person”
means any natural person, corporation, partnership, firm, joint venture, association, joint stock company, trust, unincorporated
organization, governmental body or other entity.

 

(i)          
“Subsidiary” means any corporation or other business entity directly or indirectly controlled by the corporation
in question.

 

[SIGNATURE PAGE FOLLOWS]

 

    	 	14	 

     

    

 

Exhibit 10.1

 

 

IN WITNESS WHEREOF, the parties have executed
this Agreement as of the date first above written.

 

	 	ARIAD PHARMACEUTICALS, INC.
	 	 	 
	 	 	 
	 	 	 
	 	By:	/s/ Paris Panayiotopoulos
	 	 	Paris Panayiotopoulos
	 	 	President and Chief Executive Officer
	 	 	 
	 	 	 
	 	 	 
	 	EMPLOYEE
	 	 	 
	 	 	 
	 	 	 
	 	By:	/s/ Elona Kogan
	 	 	Elona Kogan

 

    	 	15

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00264-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00264-of-00352.parquet"}]]